takotsubo syndrome
Catecholamine surge → transient LV dysfunction (classically apical ballooning with basal hyperkinesis) beyond one coronary territory, usually in a post-menopausal woman after a physical or emotional trigger. Presents as ACS — STE → angiography first. In-hospital shock and death rates match ACS; ~1 in 5 has a serious complication. Key acute decisions: look for LVOTO (~20%) before giving inotropes or nitrates, watch QTc (torsades days 2–4), consider anticoagulation for large apical akinesis. ACEi/ARB after discharge; beta-blockers don’t prevent recurrence.
recognition
InterTAK diagnostic criteria:
- Transient LV dysfunction — apical (typical), midventricular, basal or focal; RV involved in ~⅓; usually beyond one coronary territory (focal type may fit one)
- Emotional, physical or combined trigger — common, not required (~⅓ have none)
- Neurological triggers (SAH, stroke/TIA, seizure) and phaeochromocytoma count
- New ECG change — ST elevation or depression, TWI, QTc prolongation (rarely none)
- Troponin/CK moderately raised; BNP markedly raised
- Obstructive CAD does not exclude it (10–29%; WMA extends beyond the stenosed territory)
- No infectious myocarditis — CMR to confirm and exclude
- Mostly post-menopausal women (~90%, mean 67–70 y)
- Physical triggers (more common; men): respiratory failure, sepsis, surgery, pancreatitis, thyrotoxicosis, chemotherapy, alcohol/opiate withdrawal, exogenous catecholamines, dobutamine stress, β-agonists.
- Basal type → think phaeochromocytoma, adrenaline exposure, SAH.
- 5th UDMI: catecholamine-mediated acute myocardial injury, not MI → myocardial injury and MI classification.
ECG and biomarkers
| feature | takotsubo | anterior STEMI |
|---|---|---|
| ST elevation | 44%; centred V2–V5, II, aVR (−aVR); less in V1; inferior-only rare | V1–V4, I, aVL |
| ST depression | <10% | >30% → favours ACS |
| T waves / QTc | progressive deep, widespread TWI + QTc prolongation over days | — |
| Q waves | 15% | 69% |
| troponin | admission similar to ACS, peak much lower; WMA ≫ necrosis | — |
| BNP / NT-proBNP | markedly raised, peak 24–48 h | — |
diagnostic pathway
flowchart TD
A["chest pain / dyspnoea + ECG change or troponin"] --> B{"ST elevation?"}
B -- yes --> C["urgent angiography + LV ventriculography"]
B -- no --> D{"InterTAK score >70?"}
D -- "≤70 (low/intermediate)" --> C
D -- ">70 (high, ~90%)" --> E["TTE"]
E -- "circumferential ballooning, stable" --> F["CCTA to exclude CAD"]
E -- "no circumferential pattern or unstable" --> C
C --> G{"culprit lesion explains whole WMA?"}
G -- yes --> H["ACS"]
G -- no --> I{"myocarditis red flags?<br/>viral prodrome, ↑ CRP/ESR, effusion"}
F --> I
I -- yes --> J["CMR"]
I -- no --> K["takotsubo → confirm recovery on follow-up echo"]
| InterTAK score | points |
|---|---|
| female | 25 |
| emotional trigger | 24 |
| physical trigger | 13 |
| no ST depression (except aVR) | 12 |
| psychiatric disorder | 11 |
| neurological disorder | 9 |
| QTc prolongation | 6 |
30 points → <1% probability; 50 → 18%; >70 → ~90%. Not validated for phaeochromocytoma-induced cases.
- Echo: apical ballooning with basal hyperkinesis; screen every patient for LVOTO, MR (14–25%; SAM or tethering), RV involvement, apical thrombus. LV recovers in 4–8 weeks.
- CMR (subacute): RWMA + oedema without LGE → separates from infarct (territorial LGE) and myocarditis (epicardial/patchy LGE); superior for RV involvement.
- CCTA instead of angiography: stable with low ACS suspicion, suspected recurrence, or within critical illness (sepsis, SAH, stroke) or when invasive risk is high.
complications
| complication | rate |
|---|---|
| acute HF | 12–45% |
| LVOTO | 10–25% |
| MR | 14–25% |
| cardiogenic shock | 6–20% |
| AF | 5–15% |
| LV thrombus | 2–8% |
| cardiac arrest | 4–6% |
| AV block | ~5% |
| torsades / VT / VF | 3–8.6% |
| in-hospital death | 1–4.5% |
- Predictors of in-hospital events: physical trigger, acute neurological or psychiatric illness, admission troponin >10× URL, LVEF <45%; men up to 3× mortality.
- Malignant arrhythmia peaks days 2–4 with deep anterolateral TWI and QTc >500 ms → pause-dependent torsades → treat as acquired long QT.
- Long term: death 5.6%/patient-year, MACCE 9.9%/patient-year — comparable to CAD. Recurrence ~5% (3 weeks–4 years; ~1.8%/patient-year), may take a different pattern.
management
Consensus only (evidence level C) — no RCTs.
| setting | do | avoid |
|---|---|---|
| first contact | treat as ACS: ASA, heparin; ECG monitoring | — |
| mild, no HF | telemetry ≥48 h; consider ACEi/ARB, beta-blocker | — |
| pulmonary oedema | ACEi/ARB, beta-blocker; diuretic and nitroglycerin only if no LVOTO | — |
| shock with LVOTO | IV fluid (if no HF), short-acting beta-blocker, Impella | inotropes, diuretics, nitroglycerin, IABP |
| shock, primary pump failure | levosimendan, Impella, VA-ECMO | catecholamines (adrenaline, noradrenaline, dobutamine, milrinone, isoproterenol) — ~20% mortality on catecholamines |
| torsades / VT / AV block | consider beta-blocker; temporary pacing for AV block; wearable defibrillator if QTc very long or VT/VF | QT-prolonging drugs; beta-blocker with bradycardia and QTc >500 ms (caution); permanent devices (ICD of uncertain value — reversible) |
| LV thrombus, or consider if LVEF ≤30% / large apical akinesis | heparin → OAC ([[warfarin | VKA]] or [[direct oral anticoagulants |
- Beta-blockers may relieve LVOTO but are contraindicated in severe HF with low LVEF, hypotension or bradycardia.
- After discharge: ACEi/ARB for ≥3 months or until WMA recovers (1-year survival benefit, fewer recurrences — uncertain, needs validation); beta-blockers — no survival benefit, ⅓ recur on them; ASA + statin only if coexisting CAD; psycho-cardiac rehab for depression/anxiety; HRT listed for recurrence prevention in the algorithm, but the text calls oestrogen supplementation questionable.
- Shock management detail → cardiogenic shock, vasoactive drugs.
Prepared 2026-10-19. Not yet verified — check every number against the sources.